DM1-SMe

• CAT Number: I005978
• CAS Number: 138148-68-2
• Molecular Formula: C36H50ClN3O10S2
• Molecular Weight: 784.4
• Purity: ≥95%
• Target: microtubular inhibitor
• Solubility: Soluble in DMSO, not in water
• Storage: Store at -20°C
• InChI: InChI=1S/C36H50ClN3O10S2/c1-20-11-10-12-27(47-8)36(45)19-26(48-34(44)38-36)21(2)32-35(4,50-32)28(49-33(43)22(3)39(5)29(41)13-14-52-51-9)18-30(42)40(6)24-16-23(15-20)17-25(46-7)31(24)37/h10-12,16-17,21-22,26-28,32,45H,13-15,18-19H2,1-9H3,(H,38,44)/b12-10-,
• InChIKey: ZLUUPZXOPGORNG-JLZGXKMHSA-N
• SMILES: C[C@@]1([C@@H](O1)[C@H](C)[C@]([H])(C[C@](N2)(O)[C@]([H])(OC)/C=C/C=C(CC3=CC(OC)=C(Cl)C4=C3)C)OC2=O)[C@@]([H])(OC([C@@H](N(C)C(CCSSC)=O)C)=O)CC(N4C)=O

DM1-SMe (CAT: I005978) is a potent maytansinoid microtubule inhibitor. It is an unconjugated form of DM1, which is a cytotoxic compound derived from the natural product maytansine. DM1-SMe contains a mixed disulfide bond with thiomethane, which acts to cap its sulfhydryl group. This capped sulfhydryl group allows for the conjugation of DM1-SMe to the sulfhydryl group of an antibody, forming an antibody-drug conjugate (ADC). ADCs are used in targeted cancer therapy to selectively deliver cytotoxic agents, such as DM1-SMe, to cancer cells expressing specific antigens.

Reference

1:Wood AC, Maris JM, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Wu J, Kurmasheva RT, Whiteman K, Houghton PJ, Smith MA. Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013 Nov;60(11):1860-7. doi: 10.1002/pbc.24647. Epub 2013 Jun 24. PubMed PMID: 23798344; PubMed Central PMCID: PMC4260400.